CClinicalTrials.gg
Not yet recruitingNCT05613504Updated Nov 16, 2022

Study of Acupuncture in the Treatment of Hot Flashes in Patients With Hormone Receptor-positive Breast Cancer.

An interventional study of Acupuncture treatment and Sham acupuncture treatment in Hot Flashes, Breast Cancer and Acupuncture, sponsored by Nanjing University of Traditional Chinese Medicine. Not yet recruiting at 1 site in China. Open to female participants aged 30 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-11-16.

Sponsored by Nanjing University of Traditional Chinese Medicine · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
30 Years to 75 Years
Sex
Female
01

Study summary

This study intends to further evaluate the efficacy of acupuncture by comparing the intervention effects of different acupuncture treatment regimens on hot flashes in breast cancer ; and to explore the central effect regulation mechanism of acupuncture intervention on hot flashes based on integrated PET/MRI technology.

Read the detailed description

This topic combines the theory of "unblocking the governor and warming the yang" with the important findings of modern research, that is, the important mechanism of the spine in the pathogenesis of breast cancer, and innovatively proposes the technique of unblocking the governor and treating the spine. Prospective clinical intervention research in rehabilitation, objectively evaluate the clinical efficacy, advantages and disadvantages of this technology, so as to effectively break through the current application dilemma of acupuncture and bone-setting manipulation in tumor diseases.

02

Conditions studied

  • Hot Flashes
  • Breast Cancer
  • Acupuncture

Keywords

  • breast cancer
  • Acupuncture
  • Integrated PET/MRI technology
  • Hot flashes
03

Who can participate

Ages eligible
30 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Aged 30-75 years old;
  • Adjuvant hormone therapy (eg, tamoxifen and/or aromatase inhibitors) with or without ovarian function suppression has been administered for at least 4 weeks and is currently on treatment;
  • Patients with persistent hot flashes for at least 4 weeks and with a frequency of more than 14 hot flashes per week (2 times per day) in the week before inclusion in the study, the weekly average hot flash composite score is 3-4;
  • Patients after surgery and chemotherapy (if any);
  • Eastern Cooperative Oncology Group score of 0-1 points.
  • Sign the informed consent and participate in the clinical observation voluntarily.

Exclusion criteria

Exclusion Criteria:

  • Tumor metastases, undergoing chemoradiotherapy or planning surgery;
  • Pharmacological intervention for hot flashes with hot flash treatment drugs such as selective serotonin reuptake inhibitors (SSRIs) and/or anticonvulsants for at least 4 weeks prior to study initiation;
  • Patients receiving phytoestrogens, tibolone or analogs, verapril, or specific homeopathic medicines;
  • Started or changed adjuvant hormone therapy within the past week, or who planned to start or change adjuvant hormone therapy in the past 14 weeks, pregnant or breastfeeding patients;
  • Bleeding or coagulation disorders with obvious uncontrolled infection
  • Psychiatric illness or family history; neurological disorder or family history; seizure possibility or history of seizures.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Active comparator
    Treatment group A

    Treatment group A was given endocrine and acupuncture treatment for 8 weeks (24 times in total, 3 times a week); followed up for 16 weeks, no acupuncture treatment.

    Other: Acupuncture treatment

  • Sham comparator
    Treatment group B

    Treatment group B was given endocrine and sham acupuncture treatment for 8 weeks, followed up for 16 weeks, no acupuncture during the period, and after 16 weeks, received standardized acupuncture for 8 weeks (24 times in total, 3 times a week).

    Other: Sham acupuncture treatment

  • No intervention
    control

    The control group was given conventional adjuvant endocrine therapy, premenopausal patients received tamoxifen therapy, and postmenopausal patients received aromatase inhibitor or tamoxifen therapy.

Interventions

  • OtherAcupuncture treatment

    Acupoint selection: 4 general points + syndrome differentiation acupoints (select or replace 2-4 acupoints according to symptom 1, select 1-2 acupoints according to symptom 2 and symptom 3), and adjust acupoints according to symptoms every week. Frequency: 3 times a week (once every other day) for a total of 8 weeks of continuous treatment. Operation: Use a one-time sterile acupuncture needle (0.30×40mm, Huatuo brand), insert the needle 0.5 inch along the anatomical position, level up and relieve the qi, and keep the needle for 20 minutes.

  • OtherSham acupuncture treatment

    Acupoint selection: According to the selected acupoints of the electroacupuncture group, 5-7 positions were selected at the non-meridian and non-acupoint points(points with less nerve distribution, sparseness, and rich muscles). Frequency: 3 times a week (once every other day) for a total of 8 weeks of continuous treatment. Operation: ① Shallow needling scheme: use a disposable sterile acupuncture needle, insert the needle 0.2 inch, without twisting, and keep the needle for 20 minutes. ②Non-invasive acupuncture plan: choose a special comfort needle with no needle tip at the top of the needle, paste a disposable sterile foam pad on the non-acupoint, and use a disposable sterile flat head The acupuncture needles were pierced into the foam pad, lightly touching but not piercing the skin, and not breathing; the needles were kept for 20 minutes.

05

What researchers measure

Primary outcomes

  1. Change in cancer therapy functional assessment

    Cancer therapy functional assessment scores will be assessed with Cancer Therapy Functional Assessment-Breast cancer, version 4.The minimum value is 0 , and the maximum value is 185. The higher scores mean a worse outcome.

    Time frame: Baseline, 8, 12,24 weeks later

  2. Change in acupuncture efficacy expectation assessment

    Acupuncture efficacy expectation assessment scores will be assessed with acupuncture efficacy expectation assessment. The minimum value is 0 , and the maximum value is 20. The higher scores mean a better outcome.

    Time frame: Baseline, 8, 12,24 weeks later

  3. Change of functional connectivity of whole brain

    Functional connectivity will be measured with magnetic resonance imaging based on blood oxygen level dependence.

    Time frame: Baseline, 8, 12,24 weeks later

  4. Change of metabolism of glucose in the brain

    Accumulation of 18F-fluorodeoxyglucose(18F-FDG) will be analyzed by time-related Positron emission tomography.

    Time frame: Baseline, 8, 12,24 weeks later

  5. Change of hot flash severity

    Hot flash severity will be assessed with hot flash scores each week. There are four levels of severity: Mild: Duration: Less than five minutes. Symptoms: warmth, discomfort, flushing. Moderate: Duration: Up to fifteen minutes. Symptoms: warmth in head, neck, ears, or body; tense, tight muscles; clammy skin; change in heart rate or rhythm; light sweating; dry mouth. Severe: Duration: Up to twenty minutes. Symptoms: Fever, sometimes like a crucible or burning sensation; change in heart rate or rhythm; feeling faint; headache; heavy sweating. Very severe: Duration: Up to forty-five minutes. Symptoms: boiling heat; constant sweating; trouble breathing; feeling faint, dizzy; leg cramps or feeling cramps; change in heart rate; stomach upset. The greater severity mean a worse outcome.

    Time frame: Baseline, 8, 12,24 weeks later

Secondary outcomes

  1. Change in sleep

    Sleep scores will be assessed with Pittsburgh sleep quality index.The minimum value is 9, and the maximum value is 36. The higher scores mean a worse outcome.

    Time frame: Baseline, 8, 12,24 weeks later

06

Study locations

1 site
  • Jiangsu Province Hospital of Traditional Chinese Medcine
    Nanjing, Jiangsu 210029, China
07

Registry details

Key details

Study ID
NCT05613504
Lead sponsor
Nanjing University of Traditional Chinese Medicine
Collaborators
Xi'an Jiaotong University, Hanzhong Hospital of Traditional Chinese Medicine, Xiang'an Hospital of Xiamen University, Dongzhimen Hospital, Beijing
Responsible party
Qianyan Liu (Principal Investgator, Nanjing University of Traditional Chinese Medicine) — Principal investigator
First posted
Nov 14, 2022
Start date
Dec 1, 2022 (estimated)
Primary completion
Dec 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Nov 16, 2022

Study contacts

Lijun Bai, phd
Contact
bailijun@xjtu.edu.cn
0086-15129034948
Lijun Bai
study director · Xi'an Jiaotong University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion